phosphodiesterase-1 inhibitorscolitis
…days (IQR 59-214). The most common immunotherapy treatment were phosphodiesterase-1 inhibitors (49.3%).Cancer treatment common adverse events (CTCAE) grades 1…
1articles mentioning drugs
1drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: phosphodiesterase-1 inhibitors ×
phosphodiesterase-1 inhibitors
This drug is selected. Its supporting articles are shown below.